Telosis (needle-free injector)

2022: Product Announcement

In late June 2022, NovaXS Biotech introduced its intelligent medical device for needle-free injection therapy. The first indication for use that the company focuses on is in vitro fertilization.

In collaboration with the University of California, Berkeley, the company developed Telosis technology, allowing the drug to be injected with a narrow needle-free jet in 0.3 seconds and analyzed injection data for smarter health care decisions. NovaXS Biotech said in a news release that its technology represents the world's first remote drug monitoring and self-administration platform, which is a simple and painless alternative for home drug delivery.

Needle-free injector presented

{{quote 'The NovaXS Biotech team has worked hard to develop an easy-to-use needle-free solution for injectable drug delivery. We imagine a day when people living with chronic diseases will have one less care, because to administer the medicine they will need to press one button, and their attending physician will be able to remotely monitor their treatment! The mHub accelerator program provided the company with the tools and resources we need to focus on product development and gave us the opportunity to connect with new investors and industry partners, "said NovaXS Biotech Chief Operating Officer and Co-Founder Jonathan Xing. }} Xing also shared NovaXS Biotech's plans to develop the product, market potential and make a profit, noting such significant developments as the patent filing and the signing of several letters of intent with in vitro fertilization (IVF) clinics in California. The company was selected among hundreds of contenders based on its ability to meet large, unmet needs with innovative solutions that will transform patient care, the company said.^[1]

Notes